Early-Stage Antibiotic for Bone and Joint Infections Comparable to Standard of Care Therapy
December 9th 2024A small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).
Watch
More Bugs, No Drugs: The Growing Threat of Antibiotic Resistance
December 4th 2024Amesh A. Adalja, MD, FIDSA outlined the importance of recognizing antibiotic resistance in healthcare settings, educating patients on responsible antibiotic use, and the need for new treatments and diagnostic tools.
Watch
A Framework for Reducing Antimicrobial Stewardship Disparities
December 3rd 2024Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her work on the Equity in Antimicrobial Stewardship Efforts (EASE) framework, including progress for it, and how other institutions or providers can implement it.
Watch
With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.
Watch
Considering a Beta Lactam as Adjunctive Therapy for Staphylococcus aureus Early in Treatment
November 25th 2024This bacteremia can present heterogeneously and be difficult to contain, especially in an older patient population. Daniel B. Chastain, PharmD, BCIDP, AAHIVP, FIDSA, reviews the data of this class of therapies and how it may be clinically beneficial in combination with other antimicrobials.
Watch
Antimicrobial Resistance: Cause for Concern and Optimism?
November 22nd 2024Kenneth Lawrence, PharmD, discusses the global problem and the need for a layered, multifaceted approach to antimicrobial resistance (AMR) and some of the ongoing inroads and progress being made to address the medical issue.
Watch
Imdusiran for Chronic Hepatitis B Achieves Functional Cure in 50% of Patients
November 18th 2024Arbutus CEO Michael McElhaugh discussed trial results showing that a combination of imdusiran, an RNAi therapeutic, and pegylated interferon alfa-2α can achieve a functional cure in chronic hepatitis B patients.
Watch
Due to FDA Policy Change, Fecal Microbiota Transplants Are in a Tenuous Position
November 13th 2024The country’s largest fecal distributor, OpenBiome, could be prevented from offering the product next year if the FDA does not approve the product used for fecal microbiota transplants to treat fulminant C difficile.
Watch
What We Know But Still Have to Learn About Long COVID
Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
Read More
Trends in Carbapenemase-Producing Organisms: Prevalence, Treatment, and Outcomes
November 7th 2024A study of carbapenemase-producing organisms found similar rates of infections, highlighting treatment challenges, the role of rapid diagnostics, and surveillance on antimicrobial stewardship due to high mortality rates.
Read More